{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:46:13Z","timestamp":1782837973822,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12020-022-03062-3","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T05:22:23Z","timestamp":1651296143000},"page":"143-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prospective study on the clinical relevance of 18F-DOPA positron emission tomography\/computed tomography in patients with medullary thyroid carcinoma"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7450-5832","authenticated-orcid":false,"given":"In\u00e9s","family":"Califano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-7085","authenticated-orcid":false,"given":"Fabi\u00e1n","family":"Pitoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-0764","authenticated-orcid":false,"given":"Roxana","family":"Chirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-8460","authenticated-orcid":false,"given":"Alejandra","family":"De Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3254-1800","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Bastianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"issue":"6","key":"3062_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"S Wells","year":"2015","unstructured":"S. Wells, Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6), 567\u2013590 (2015). https:\/\/doi.org\/10.1089\/thy.2014.0335","journal-title":"Thyroid"},{"issue":"4","key":"3062_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ejso.2006.10.021","volume":"33","author":"MR Pelizzo","year":"2007","unstructured":"M.R. Pelizzo, Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur. J. Surg. Oncol. 33(4), 493\u2013497 (2007). https:\/\/doi.org\/10.1016\/j.ejso.2006.10.021","journal-title":"Eur. J. Surg. Oncol."},{"issue":"8","key":"3062_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.endonu.2014.02.006","volume":"61","author":"L Louhibi","year":"2014","unstructured":"L. Louhibi, Demographic, clinical, and genetic characteristics of patients with medullary thyroid cancer in the past 16 years in Castilla-La Mancha. Endocrinol. Nutr. 61(8), 398\u2013403 (2014). https:\/\/doi.org\/10.1016\/j.endonu.2014.02.006","journal-title":"Endocrinol. Nutr."},{"issue":"2","key":"3062_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/1874471011306020006.","volume":"6","author":"KS Slavikova","year":"2013","unstructured":"K.S. Slavikova, What is currently the best radiopharmaceutical for the hybrid PET\/CT detection of recurrent medullary thyroid carcinoma? Curr. Radiopharm. 6(2), 96\u2013105 (2013). https:\/\/doi.org\/10.2174\/1874471011306020006.","journal-title":"Curr. Radiopharm."},{"issue":"12","key":"3062_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"S. Filetti, Thyroid Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Ann. Oncol. 30(12), 1856\u20131883 (2019). https:\/\/doi.org\/10.1093\/annonc\/mdz400","journal-title":"Ann. Oncol."},{"issue":"11","key":"3062_CR6","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1210\/jc.2007-1211","volume":"92","author":"A Giraudet","year":"2007","unstructured":"A. Giraudet, Imaging medullary thyroid carcinoma with persistently elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92(11), 4185\u20134190 (2007). https:\/\/doi.org\/10.1210\/jc.2007-1211","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3062_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12020-012-9671-6","volume":"42","author":"G Treglia","year":"2012","unstructured":"G. Treglia, Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 42, 535\u2013545 (2012). https:\/\/doi.org\/10.1007\/s12020-012-9671-6","journal-title":"Endocrine"},{"issue":"8","key":"3062_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4158\/EP171806.OR","volume":"23","author":"J Yang","year":"2017","unstructured":"J. Yang, The combined use of calcitonin doubling time and 18F-FDG PET\/CT improves prognostic values in medullary thyroid carcinoma: the clinical utility of 18F-FDG PET\/CT. Endocr. Pr. 23(8), 942\u2013948 (2017). https:\/\/doi.org\/10.4158\/EP171806.OR","journal-title":"Endocr. Pr."},{"issue":"7","key":"3062_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1507\/endocrj.EJ16-0140","volume":"63","author":"Y Ito","year":"2016","unstructured":"Y. Ito, Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients\u2019 carcinoma death. Endocr. J. 63(7), 663\u2013667 (2016). https:\/\/doi.org\/10.1507\/endocrj.EJ16-0140","journal-title":"Endocr. J."},{"issue":"1","key":"3062_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00259-019-04458-6.","volume":"47","author":"L Giovanella","year":"2020","unstructured":"L. Giovanella, EAMN practice guideline for PET TC imaging in medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. 47(1), 61\u201377 (2020). https:\/\/doi.org\/10.1007\/s00259-019-04458-6.","journal-title":"Eur. J. Nucl. Med. Mol."},{"key":"3062_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/jcbfm.1991.154","volume":"11","author":"W Melega","year":"1991","unstructured":"W. Melega, L-6-e8F]Fluoro-DOPA Metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J. Cereb. Blood Flow. Metab. 11, 890\u2013897 (1991). https:\/\/doi.org\/10.1038\/jcbfm.1991.154","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"3062_CR12","first-page":"32","volume":"37","author":"M Bergstr\u00f6m","year":"1996","unstructured":"M. Bergstr\u00f6m, In vivo demostration of enzyme actity in endocrime pancreatric tumors: decarboxylation of carbon 11 DOPA to carbon 11 dopamine. J. Nucl. Med. 37, 32\u201337 (1996)","journal-title":"J. Nucl. Med."},{"issue":"1","key":"3062_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s002590000404","volume":"28","author":"S Hoegerle","year":"2001","unstructured":"S. Hoegerle, 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur. J. Nucl. Med. 28(1), 64\u201371 (2001). https:\/\/doi.org\/10.1007\/s002590000404","journal-title":"Eur. J. Nucl. Med."},{"key":"3062_CR14","unstructured":"R. Haddad, NCCN Guidelines version 2.2021. Thyroid carcinoma. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf. Accessed 10\/15\/2021"},{"issue":"6","key":"3062_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00259-015-3227-y","volume":"43","author":"A Archier","year":"2016","unstructured":"A. Archier, (18)F-DOPA PET\/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 43(6), 1027\u20131033 (2016). https:\/\/doi.org\/10.1007\/s00259-015-3227-y","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"32","key":"3062_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12149-017-1213-0","volume":"1","author":"F Caobelli","year":"2018","unstructured":"F. Caobelli, Predictive and prognostic value of 18F-DOPA PET\/CT in patients affected by recurrent medullary carcinoma of the thyroid. Ann. Nucl. Med. 1(32), 7\u201315 (2018). https:\/\/doi.org\/10.1007\/s12149-017-1213-0","journal-title":"Ann. Nucl. Med."},{"key":"3062_CR17","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1007\/s00259-019-04332-5","volume":"46","author":"W Noordzij","year":"2019","unstructured":"W. Noordzij, Adrenal tracer uptake by 18F-FDOPA PET\/CT in patients with pheochromocytoma and controls. Eur. J. Nucl. Med. Mol. Imaging 46, 1560\u20131566 (2019). https:\/\/doi.org\/10.1007\/s00259-019-04332-5","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"3062_CR18","doi-asserted-by":"publisher","unstructured":"L. Brammen, Medullary thyroid carcinoma: do ultrasonography and F-DOPA-PET-CT influence the initial surgical strategy? Ann Surg. Oncol. 3919\u20133927 (2018). https:\/\/doi.org\/10.1245\/s10434-018-6829-3","DOI":"10.1245\/s10434-018-6829-3"},{"issue":"12","key":"3062_CR19","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00259-018-4045-9","volume":"45","author":"S Rasul","year":"2018","unstructured":"S. Rasul, 18 F DOPA PET \/TC in diagnosis and stating of primary thyroid carcinoma prior to surgery. Eur. J. Nucl. Mol. Imaging 45(12), 2159\u20132149 (2018). https:\/\/doi.org\/10.1007\/s00259-018-4045-9","journal-title":"Eur. J. Nucl. Mol. Imaging"},{"key":"3062_CR20","doi-asserted-by":"publisher","unstructured":"M. Terroir, F-18-Dopa PET\/CT is more sensitive than whole body MRI for the localization of persistent\/recurrent disease of medullary thyroid. Thyroid 29 (10), 1457\u20131464, https:\/\/doi.org\/10.1089\/thy.2018.0351","DOI":"10.1089\/thy.2018.0351"},{"key":"3062_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/RLU.0000000000002940","volume":"45","author":"S Lee","year":"2020","unstructured":"S. Lee, Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a network meta-analysis. Clin. Nucl. Med. 45, 341\u2013348 (2020). https:\/\/doi.org\/10.1097\/RLU.0000000000002940","journal-title":"Clin. Nucl. Med."},{"key":"3062_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00259-011-2031-6","volume":"39","author":"G Treglia","year":"2012","unstructured":"G. Treglia, Comparison of 18-F DOPA, 18-F FDG and 68Ga-Somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 39, 569\u2013580 (2012). https:\/\/doi.org\/10.1007\/s00259-011-2031-6. 569-580","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"3062_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/thy.2020.0674","volume":"31","author":"F Castinetti","year":"2021","unstructured":"F. Castinetti, PET imaging in medullary thyroid carcinoma:time for reappraisal? Thyroid 31(2), 151\u2013155 (2021). https:\/\/doi.org\/10.1089\/thy.2020.0674","journal-title":"Thyroid"},{"key":"3062_CR24","doi-asserted-by":"crossref","unstructured":"F. Calabria, 18 F- DOPA . In: Radiopharmaceuticals. A guide to PET\/CT and PET\/MRI, ed. F. Calabria, O. Schillaci (Springer Nature Switzerland AG) (2020, second edition), p. 37\u201357.","DOI":"10.1007\/978-3-030-27779-6_2"}],"updated-by":[{"DOI":"10.1007\/s12020-022-03093-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000}}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03062-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03062-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03062-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T15:49:50Z","timestamp":1656517790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03062-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3062"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03062-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12020-022-03093-w","asserted-by":"object"}]},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12020-022-03093-w","URL":"https:\/\/doi.org\/10.1007\/s12020-022-03093-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from every participant patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}